BioCentury | Dec 7, 2009
Strategy

Meeting the Biota Quota

...Biota Holdings Ltd. 's acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline...
...its facilities in Oxford, U.K., and will offer Prolysis founder Jeff Errington a board seat. MaxThera...
...eligible for 12% of upfront and milestone payments if Biota out-licenses MaxThera's two main programs. MaxThera...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

...Holdings Ltd. (ASX:BTA) gained A$0.03 to $2.68 last week after acquiring fellow infectious disease companies MaxThera Inc....
...receive A$10.8 million ($10 million) in Biota stock, for a 2.2% stake in Biota, while MaxThera...
BioCentury | Nov 16, 2009
Company News

Biota, MaxThera Inc., Prolysis deal

...Biota acquired fellow infectious disease companies MaxThera and Prolysis. Prolysis shareholders will receive A$10.8 million ($10...
...all upfront and milestone payments received by Biota if Biota out-licenses MaxThera's two main programs. MaxThera...
...of Medicinal Chemistry Roger Frechette, both founders of MaxThera, will continue the programs at the MaxThera...
BioCentury | Nov 13, 2009
Company News

Biota acquires MaxThera, Prolysis

...Biota Holdings Ltd. (ASX:BTA) acquired fellow infectious disease companies MaxThera Inc. (Boston, Mass.) and Prolysis Ltd. (Yarnton...
...receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota, while MaxThera...
...to 15% of all milestones and royalties received by Biota should Prolysis' programs be out-licensed. MaxThera...
Items per page:
1 - 4 of 4
BioCentury | Dec 7, 2009
Strategy

Meeting the Biota Quota

...Biota Holdings Ltd. 's acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline...
...its facilities in Oxford, U.K., and will offer Prolysis founder Jeff Errington a board seat. MaxThera...
...eligible for 12% of upfront and milestone payments if Biota out-licenses MaxThera's two main programs. MaxThera...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

...Holdings Ltd. (ASX:BTA) gained A$0.03 to $2.68 last week after acquiring fellow infectious disease companies MaxThera Inc....
...receive A$10.8 million ($10 million) in Biota stock, for a 2.2% stake in Biota, while MaxThera...
BioCentury | Nov 16, 2009
Company News

Biota, MaxThera Inc., Prolysis deal

...Biota acquired fellow infectious disease companies MaxThera and Prolysis. Prolysis shareholders will receive A$10.8 million ($10...
...all upfront and milestone payments received by Biota if Biota out-licenses MaxThera's two main programs. MaxThera...
...of Medicinal Chemistry Roger Frechette, both founders of MaxThera, will continue the programs at the MaxThera...
BioCentury | Nov 13, 2009
Company News

Biota acquires MaxThera, Prolysis

...Biota Holdings Ltd. (ASX:BTA) acquired fellow infectious disease companies MaxThera Inc. (Boston, Mass.) and Prolysis Ltd. (Yarnton...
...receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota, while MaxThera...
...to 15% of all milestones and royalties received by Biota should Prolysis' programs be out-licensed. MaxThera...
Items per page:
1 - 4 of 4